Abstract:oral, once-daily ibrutinib 560 mg plus venetoclax in a 5-week rampup to 400 mg. Treatment will continue for up to 24 months, after which venetoclax will be discontinued in all patients and singleagent ibrutinib will continue until progressive disease or unacceptable toxicity. The primary objective is to evaluate the CR rate; secondary objectives include additional efficacy evaluations, safety, and pharmacokinetics. Status: The new arm of the SYMPATICO study conducted in previously untreated patients is current… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.